NASDAQ · Biotechnology

Allogene Therapeutics, Inc. (ALLO) Stock

$1.40 -2.10% NASDAQ: ALLO Healthcare

Valuation

MetricValue
Price$1.40
Market Cap$483.22M
P/E Ratio-2.24
P/B Ratio1.13
P/S Ratio111.58
EPS (TTM)$-0.87
52-Week High$4.46
52-Week Low$1.04
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-50.04%
ROA-30.08%
ROCE-34.79%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.16
Current Ratio7.82

Annual Financials (USD)

Metric20212022202320242025
Revenue$114.0M$0$0$0$0
Operating Profit$-180.0M$-336.0M$-328.0M$-273.0M$-207.0M
Net Profit$-182.0M$-340.0M$-327.0M$-258.0M$-191.0M
EPS$-1.34$-2.38$-2.09$-1.32$-0.87
Op Margin-157.9%-215087.2%-344986.3%-1241813.6%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.1B$822.0M$643.0M$549.0M$416.0M
Total Liabilities$126.0M$155.0M$131.0M$127.0M$123.0M
Cash$173.0M$62.0M$83.0M$75.0M$52.0M
Borrowings$73.0M$101.0M$95.0M$91.0M$83.0M

Latest News

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors GlobeNewswire · Jul 15, 2026 Kyverna Therapeutics Sinks 13%: Here’s Why 24/7 Wall St. · Jul 10, 2026 Imviva Biotech Granted FDA IDE Authorization for Cancer Treatment Trial Exec Edge · Jun 30, 2026 Allogene Therapeutics (ALLO) Stock Gets Fair Value Boost After Split Analyst Revisions Simply Wall St. · Jun 28, 2026 How Allogene Therapeutics (ALLO) Is Expanding Its Off-the-Shelf CAR T Platform Across Cancer and Autoimmune Disease Insider Monkey · Jun 17, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-185.0M$-221.0M$-238.0M$-200.0M$-149.0M
Investing Cash Flow$142.0M$101.0M$162.0M$75.0M$95.0M
Financing Cash Flow$0$0$5.0M$2.0M$7.0M
Net Cash Flow$-9.0M$-111.0M$21.0M$-8.0M$-24.0M
Free Cash Flow$-206.0M$-226.0M$-239.0M$-201.0M$-150.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.04
EV / EBITDA-3.60
FCF Yield-19.82%
Quick Ratio10.72
Interest Coverage-138.71
Return 1Y9.64%
Return 3Y-63.16%
Return 5Y-91.72%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATRAAtara Biotherapeutics, Inc. $9.23 -1.49% -7.94 $83.16M 0.00%
AUTLAutolus Therapeutics plc $1.46 -13.61% -1.35 — 0.00%
CELUCelularity Inc. $1.46 -0.68% -0.51 $42.26M 0.00%
CLLSCellectis S.A. $2.81 -2.26% -4.14 $282.17M 0.00%
CRBUCaribou Biosciences, Inc. $0.48 -22.06% -1.13 $47.73M 0.00%

About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. is led by CEO David D. Chang, publicly traded since 2018.

Allogene Therapeutics, Inc. (ALLO) stock trades at $1.40 with a market capitalization of $483.22M. The stock is valued at a price-to-earnings (P/E) ratio of -2.24, price-to-book of 1.13, price-to-sales of 111.58. Over the past 52 weeks the stock has ranged between $1.04 and $4.46, and currently trades 68.6% below its 52-week high.

On profitability, Allogene Therapeutics, Inc. generates a return on equity (ROE) of -50.04%, return on capital employed of -34.79%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1169.93 -1.58% JNJ Johnson & Johnson $256.48 -0.76% ABBV AbbVie Inc. $272.42 +0.39% MRK Merck & Company, Inc. Common Stock (new) $142.40 -0.28% UNH UnitedHealth Group Incorporated Common Stock (DE) $370.95 -1.34% NVS Novartis AG $143.11 -0.12% AZN AstraZeneca PLC $158.78 -0.84% TMO Thermo Fisher Scientific Inc $651.98 -1.52% AMGN Amgen Inc. $407.44 -1.37% GILD Gilead Sciences, Inc. $147.10 +0.17% ABT Abbott Laboratories $98.49 -0.24% NVO Novo Nordisk A/S $38.18 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides